Literature DB >> 17982458

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells.

Pushpa Pandiyan1, Lixin Zheng, Satoru Ishihara, Jennifer Reed, Michael J Lenardo.   

Abstract

A key issue in mammalian immunology is how CD4+CD25+Foxp3+ regulatory T cells (T(reg) cells) suppress immune responses. Here we show that T(reg) cells induced apoptosis of effector CD4+ T cells in vitro and in vivo in a mouse model of inflammatory bowel disease. T(reg) cells did not affect the early activation or proliferation of effector CD4+ T cells. Cytokines that signal through the common gamma-chain suppressed T(reg) cell-induced apoptosis. T(reg) cell-induced effector CD4+ T cell death required the proapoptotic protein Bim, and effector CD4+ T cells incubated with T(reg) cells showed less activation of the prosurvival kinase Akt and less phosphorylation of the proapoptotic protein Bad. Thus, cytokine deprivation-induced apoptosis is a prominent mechanism by which T(reg) cells inhibit effector T cell responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982458     DOI: 10.1038/ni1536

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  466 in total

1.  CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses.

Authors:  Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism.

Authors:  Alicia Benson; Sean Murray; Prashanthi Divakar; Nikolay Burnaevskiy; Reed Pifer; James Forman; Felix Yarovinsky
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

Review 3.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

4.  Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells.

Authors:  Xuguang Tai; François Van Laethem; Leonid Pobezinsky; Terry Guinter; Susan O Sharrow; Anthony Adams; Larry Granger; Michael Kruhlak; Tullia Lindsten; Craig B Thompson; Lionel Feigenbaum; Alfred Singer
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 5.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

Review 6.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

7.  Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2.

Authors:  Guangxian Liu; Wuwei Yang; Mei Guo; Xiaoqing Liu; Naixiang Huang; Dingfeng Li; Zefei Jiang; Wenfeng Yang; Weijing Zhang; Hang Su; Zhiqing Liu; Tieqiang Liu; Dongmei Wang; Shan Huang; Bo Yao; Qiuhong Man; Lijuan Qiu; Xuedong Sun; Yuying Sun; Bing Liu
Journal:  Cancer Immunol Immunother       Date:  2012-06-22       Impact factor: 6.968

8.  Analysis of adhesion molecules, target cells, and role of IL-2 in human FOXP3+ regulatory T cell suppressor function.

Authors:  Dat Q Tran; Deborah D Glass; Gulbu Uzel; Dirk A Darnell; Christine Spalding; Steven M Holland; Ethan M Shevach
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors:  David A Horwitz; Stephanie Pan; Jing-Ni Ou; Julie Wang; Maogen Chen; J Dixon Gray; Song Guo Zheng
Journal:  Clin Immunol       Date:  2013-08-20       Impact factor: 3.969

10.  Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

Authors:  Christian A Bauer; Edward Y Kim; Francesco Marangoni; Esteban Carrizosa; Natalie M Claudio; Thorsten R Mempel
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.